PTC Therapeutics公司、Royalty Pharma Investments 2019 Icav基金以及Royalty Pharma Plc共同宣布，三方已正式签署购买协议的第二号修正案。此次修订旨在优化原有条款，进一步明确各方的权利与义务。
该修正案涉及对原始购买协议中特定条款的调整，反映出合作方在不断变化的市场环境中寻求更高效协作的努力。协议的更新将有助于提升合作透明度，为未来业务发展奠定更稳固的基础。
PTC Therapeutics公司、Royalty Pharma Investments 2019 Icav基金以及Royalty Pharma Plc共同宣布，三方已正式签署购买协议的第二号修正案。此次修订旨在优化原有条款，进一步明确各方的权利与义务。
该修正案涉及对原始购买协议中特定条款的调整，反映出合作方在不断变化的市场环境中寻求更高效协作的努力。协议的更新将有助于提升合作透明度，为未来业务发展奠定更稳固的基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.